Analyst Stock Ratings Initiations

Buy NowGet Alert
07/12/2024SCCOBuy Now
Southern Copper
$113.056.15%UBS
Myles Allsop44%
 → $120Initiates → NeutralGet Alert
07/12/2024RVMDBuy Now
Revolution Medicines
$46.7511.23%Barclays
Peter Lawson48%
 → $52Initiates → OverweightGet Alert
07/12/2024SWBuy Now
Smurfit WestRock
$48.3536.5%JP Morgan
Detlef Winckelmann53%
 → $66Initiates → OverweightGet Alert
07/12/2024STAGBuy Now
Stag Industrial
$37.960.11%Wedbush
Richard Anderson70%
 → $38Initiates → NeutralGet Alert
07/12/2024JILLBuy Now
J.Jill
$37.6017.02%Jefferies
Corey Tarlowe69%
 → $44Initiates → BuyGet Alert
07/12/2024AVBHBuy Now
Avidbank Holdings
$18.9510.82%Janney Montgomery Scott
Timothy Coffey60%
 → $21Initiates → NeutralGet Alert
07/12/2024CVNABuy Now
Carvana
$143.008.39%BTIG
Marvin Fong64%
 → $155Initiates → BuyGet Alert
07/12/2024GWHBuy Now
ESS Tech
$0.8870.84%Roth MKM
Justin Clare38%
 → $1.5Initiates → BuyGet Alert
07/12/2024KNSLBuy Now
Kinsale Cap Gr
$398.54—Oppenheimer
Michael Phillips52%
—Initiates → PerformGet Alert
07/12/2024SKWDBuy Now
Skyward Specialty
$38.00—Oppenheimer
Michael Phillips52%
—Initiates → PerformGet Alert
07/12/2024SPOTBuy Now
Spotify Technology
$304.0028.29%Wolfe Research
Devin Brisco63%
 → $390Initiates → OutperformGet Alert
07/12/2024SWBuy Now
Smurfit WestRock
$48.357.55%RBC Capital
Matthew McKellar36%
 → $52Initiates → Sector PerformGet Alert
07/11/2024FLNCBuy Now
Fluence Energy
$16.8224.85%Scotiabank— → $21Initiates → Sector PerformGet Alert
07/11/2024YMABBuy Now
Y-mAbs Therapeutics
$12.9877.2%Jones Trading
Justin Walsh59%
 → $23Initiates → BuyGet Alert
07/11/2024ZPTABuy Now
Zapata Computing Holdings
$0.65129.78%Benchmark
Matthew Harrigan53%
 → $1.5Initiates → Speculative BuyGet Alert
07/11/2024UNMBuy Now
Unum Gr
$52.957.65%Piper Sandler
John Barnidge73%
 → $57Initiates → OverweightGet Alert
07/11/2024CDROBuy Now
Codere Online Luxembourg
$8.0823.76%Craig-Hallum
Chase Knickerbocker47%
 → $10Initiates → BuyGet Alert
07/11/2024RBBNBuy Now
Ribbon Comms
$3.8430.21%Rosenblatt
Mike Genovese56%
 → $5Initiates → BuyGet Alert
07/11/2024VNDABuy Now
Vanda Pharma
$6.0581.82%Cantor Fitzgerald
Charles Duncan70%
 → $11Initiates → OverweightGet Alert
07/11/2024NIBuy Now
NiSource
$29.7311%Mizuho
Gabriel Moreen76%
 → $33Initiates → OutperformGet Alert
07/11/2024CARTBuy Now
Maplebear
$34.99—Keybanc
Justin Patterson67%
—Initiates → Sector WeightGet Alert
07/11/2024DASHBuy Now
DoorDash
$106.00—Keybanc
Justin Patterson67%
—Initiates → Sector WeightGet Alert
07/11/2024EQIXBuy Now
Equinix
$804.668.49%Mizuho
Vikram Malhotra55%
 → $873Initiates → OutperformGet Alert
07/11/2024DLRBuy Now
Digital Realty Trust
$158.996.92%Mizuho
Omotayo Okusanya60%
 → $170Initiates → OutperformGet Alert
07/10/2024CXWBuy Now
CoreCivic
$14.50—Jones Trading
Jason Weaver48%
—Initiates → HoldGet Alert
07/10/2024GEOBuy Now
GEO Group
$17.795.4%Jones Trading
Jason Weaver48%
 → $18.75Initiates → BuyGet Alert
07/10/2024GRPNBuy Now
Groupon
$16.6831.89%Northland Capital Markets
Bobby Brooks69%
 → $22Initiates → OutperformGet Alert
07/10/2024CNLBuy Now
Collective Mining
——Roth MKM
Mike Niehuser43%
 → $5Initiates → BuyGet Alert
07/10/2024FLNCBuy Now
Fluence Energy
$16.8248.63%Truist Securities
Jordan Levy37%
 → $25Initiates → BuyGet Alert
07/10/2024BHCBuy Now
Bausch Health Companies
$7.299.74%Raymond James
Michael Freeman1%
 → $8Initiates → Market PerformGet Alert
07/10/2024BLCOBuy Now
Bausch & Lomb
$16.2017.28%Raymond James
Gary Nachman54%
 → $19Initiates → OutperformGet Alert
07/10/2024HIBuy Now
Hillenbrand
$43.0316.2%Keybanc
Jeffrey Hammond73%
 → $50Initiates → OverweightGet Alert
07/10/2024ATKRBuy Now
Atkore
$144.7620.89%Keybanc
Jeffrey Hammond73%
 → $175Initiates → OverweightGet Alert
07/10/2024REXRBuy Now
Rexford Industrial Realty
$49.988.04%Evercore ISI Group
Samir Khanal52%
 → $54Initiates → OutperformGet Alert
07/10/2024WGSBuy Now
GeneDx Hldgs
$34.5024.64%Craig-Hallum
Bill Bonello58%
 → $43Initiates → BuyGet Alert
07/10/2024EHCBuy Now
Encompass Health
$85.4916.97%Leerink Partners
Whit Mayo69%
 → $100Initiates → OutperformGet Alert
07/10/2024MKSIBuy Now
MKS Instruments
$142.7512.08%B of A Securities
Vivek Arya85%
 → $160Initiates → BuyGet Alert
07/10/2024CMPOBuy Now
CompoSecure
$7.6817.19%B of A Securities
Cassie Chan15%
 → $9Initiates → BuyGet Alert
07/10/2024JILLBuy Now
J.Jill
$37.6017.02%BTIG
Janine Stichter64%
 → $44Initiates → BuyGet Alert
07/10/2024MLYSBuy Now
Mineralys Therapeutics
$14.58105.76%HC Wainwright & Co.
Matthew Caufield37%
 → $30Initiates → BuyGet Alert
07/10/2024LEXXBuy Now
Lexaria Bioscience
$2.82254.61%HC Wainwright & Co.
Yi Chen56%
 → $10Initiates → BuyGet Alert
07/10/2024IRENBuy Now
Iris Energy
$11.94117.76%Bernstein
Gautam Chhugani57%
 → $26Initiates → OutperformGet Alert
07/10/2024CORZBuy Now
Core Scientific
$10.8956.11%Bernstein
Gautam Chhugani57%
 → $17Initiates → OutperformGet Alert
07/09/2024PMNTBuy Now
Perfect Moment
$1.55287.1%ThinkEquity
Ashok Kumar34%
 → $6Initiates → BuyGet Alert
07/09/2024SEZLBuy Now
Sezzle
$85.6538.94%Northland Capital Markets— → $119Initiates → OutperformGet Alert

Recent Analyst Stock Rating Initiation News

Mizuho Downgrades Zscaler to Neutral, Maintains Price Target to $220
Mizuho analyst Gregg Moskowitz downgrades Zscaler (NASDAQ:ZS) from Outperform to Neutral and maintains the price target from $220 to $220.
Piper Sandler Downgrades Dollar Tree to Neutral, Lowers Price Target to $112
Piper Sandler analyst Peter Keith downgrades Dollar Tree (NASDAQ:DLTR) from Overweight to Neutral and lowers the price target from $143 to $112.
JMP Securities Initiates Coverage On Option Care Health with Market Outperform Rating, Announces Price Target of $36
JMP Securities analyst Constantine Davides initiates coverage on Option Care Health (NASDAQ:OPCH) with a Market Outperform rating and announces Price Target of $36.
JMP Securities Initiates Coverage On Progyny with Market Outperform Rating, Announces Price Target of $36
JMP Securities analyst Constantine Davides initiates coverage on Progyny (NASDAQ:PGNY) with a Market Outperform rating and announces Price Target of $36.
Morgan Stanley Upgrades Sweetgreen to Equal-Weight, Announces $25 Price Target
Morgan Stanley analyst Brian Harbour upgrades Sweetgreen (NYSE:SG) from Underweight to Equal-Weight and announces $25 price target.
Stifel Upgrades Profound Medical to Buy, Raises Price Target to $12
Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.
JMP Securities Initiates Coverage On Simulations Plus with Market Perform Rating
JMP Securities analyst Constantine Davides initiates coverage on Simulations Plus (NASDAQ:SLP) with a Market Perform rating.
Roth MKM Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $20
Roth MKM analyst Jonathan Aschoff initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $20.
Oppenheimer Initiates Coverage On Integer Holdings with Outperform Rating, Announces Price Target of $135
Oppenheimer analyst Suraj Kalia initiates coverage on Integer Holdings (NYSE:ITGR) with a Outperform rating and announces Price Target of $135.
Morgan Stanley Upgrades Chegg to Equal-Weight, Lowers Price Target to $3.25
Morgan Stanley analyst Josh Baer upgrades Chegg (NYSE:CHGG) from Underweight to Equal-Weight and lowers the price target from $6.5 to $3.25.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Luke Jacobi

About Luke Jacobi

Luke Jacobi is a distinguished professional known for his role as President at Benzinga, a renowned financial media outlet. With a background in business operations and management, Luke brings valuable expertise to his position, overseeing various aspects of Benzinga’s operations. His contributions play a crucial role in the company’s success, ensuring efficiency and effectiveness across different departments. Prior to his role at Benzinga, Luke has held positions that have honed his skills in leadership and strategic decision-making. With a keen understanding of the financial industry and a commitment to driving innovation, Luke continues to make significant contributions to Benzinga’s mission of providing high-quality financial news and analysis.